Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations. 1984

C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster

One hundred two children with group A streptococcal pharyngitis were treated on a randomized basis with either 15 mg/kg of erythromycin estolate or 25 mg/kg of erythromycin ethylsuccinate given twice daily for ten days. Twelve patients, including 11 erythromycin ethylsuccinate-treated patients and one erythromycin estolate-treated patient, were dropped from the study at the request of their parents because of abdominal cramping and/or nausea and vomiting that occurred 15 to 45 minutes after ingestion of drug. Eighteen other patients (12 treated with erythromycin ethylsuccinate and six treated with erythromycin estolate) had similar gastrointestinal (GI) tract symptoms that resolved or abated. Excluding patients with reinfections with new streptococcal serotypes and those with resistant strains, the bacteriologic failure rates were 4.3% and 17.5%, and the total failure rates were 6.4% and 35.3% with erythromycin estolate therapy and with erythromycin ethylsuccinate therapy, respectively. The high rate of GI tract intolerance associated with the erythromycin ethylsuccinate appears to be dose related.

UI MeSH Term Description Entries
D008297 Male Males
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010612 Pharyngitis Inflammation of the throat (PHARYNX). Sore Throat,Pharyngitides,Sore Throats,Throat, Sore
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D004918 Erythromycin Estolate A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin Propionate Dodecyl Sulfate,Erythromycin Propionate Lauryl Sulfate,Eromycin,Erythromycin Propionate Monododecyl Sulfate,Ilosone,Lauromicina,Estolate, Erythromycin

Related Publications

C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
March 1992, The Pediatric infectious disease journal,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
November 1979, American journal of diseases of children (1960),
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
August 1982, Digestive diseases and sciences,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
January 1963, Antimicrobial agents and chemotherapy,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
January 1973, The Medical journal of Australia,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
February 1976, American journal of diseases of children (1960),
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
October 1988, The Journal of antimicrobial chemotherapy,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
September 1996, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
January 1973, The Medical journal of Australia,
C M Ginsburg, and G H McCracken, and S D Crow, and B R Dildy, and G Morchower, and J B Steinberg, and K Lancaster
May 1977, Clinical pediatrics,
Copied contents to your clipboard!